[1. Dolberg OJ, Levy Y. Idiopathic aplastic anemia: Diagnosis and classification. Autoimmun Rev. 2014;13:569-573.10.1016/j.autrev.2014.01.014]Search in Google Scholar
[2. Young NS. Acquired aplastic anemia. Ann Intern Med. 2020;136:534-546.10.7326/0003-4819-136-7-200204020-00011]Search in Google Scholar
[3. Savașan S. Acquired aplastic anemia: what have we learned and what is the horizon? Pediatr Clin North Am. 2018;65:597-606.]Search in Google Scholar
[4. Ahmed P, Chaudhry Q, Satti TM, et al. Epidemiology of aplastic anemia: a study of 1324 cases. Hematology. 2020;25:48-54.10.1080/16078454.2019.1711344]Search in Google Scholar
[5. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509-2519.10.1182/blood-2006-03-010777]Search in Google Scholar
[6. Schoentler ML, Nathan DG. The pathophysiology of acquired aplastic anemia: current concepts revisited. Hematol Oncol Clin North Am. 2018;32:581-594.10.1016/j.hoc.2018.03.001]Search in Google Scholar
[7. Camitta BM. Criteria for severe aplastic anaemia. Lancet. 1988;1:303-304.10.1016/S0140-6736(88)90388-1]Search in Google Scholar
[8. DeZern AE, Brodsky RA. Clinical management of aplastic anemia. Expert Rev Hematol. 2012;4:221-230.]Search in Google Scholar
[9. Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016:172:187-207.10.1111/bjh.1385326568159]Search in Google Scholar
[10. Scheinberg P. Recent advances and long-term results of medical treatment of acquired aplastic anemia: are pacients cured? Hematol Oncol Clin North Am. 2018;32:609-618.]Search in Google Scholar
[11. Hochsmann B, Moicean A, Risitano A, Ljungman P, Schrezenmeier H. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant. 2013;48:168-173.10.1038/bmt.2012.22023208312]Search in Google Scholar
[12. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Adv Hematol. 2012;120:1185-1196.10.1182/blood-2011-12-274019341871522517900]Search in Google Scholar
[13. Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129:1428-1436.10.1182/blood-2016-08-69348128096088]Search in Google Scholar
[14. Young NS. Aplastic anemia. N Engl J Med. 2018;379:1643-1656.10.1056/NEJMra1413485]Search in Google Scholar
[15. Camitta BM, Rappeport JM, Parkman R, Nathan DG. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood. 1973;45:355-363.10.1182/blood.V45.3.355.355]Search in Google Scholar
[16. Marsh JCW, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147:43-70.10.1111/j.1365-2141.2009.07842.x]Search in Google Scholar
[17. Passweg JR, Tichelli A. Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling? Haematologica. 2009;94:310-312.]Search in Google Scholar
[18. Frickhofen N, Rosenfeld SJ. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol. 2000;37:56-68.10.1016/S0037-1963(00)90030-1]Search in Google Scholar
[19. Rosenfeld S, Follman D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289:1130-1135.10.1001/jama.289.9.113012622583]Search in Google Scholar
[20. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 1995;85:3058-3065.10.1182/blood.V85.11.3058.bloodjournal85113058]Search in Google Scholar
[21. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999;93:2191-2195.10.1182/blood.V93.7.2191]Search in Google Scholar
[22. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and cyclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol. 2006;11:622-627.10.1111/j.1365-2141.2006.06098.x16704436]Search in Google Scholar
[23. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11-19.10.1056/NEJMoa1200931342273722762314]Search in Google Scholar
[24. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123:1818-1825.10.1182/blood-2013-10-534743396216124345753]Search in Google Scholar
[25. Winkler T, Cooper JN, Townsley DM, et al. Eltrombopag for refractory sever aplastic anemia: dosing, regiments, long-term follow-up, clonal evolution and somatic mutation profiling. Blood. 2017;130:777.10.1182/blood.V130.Suppl_1.777.777]Search in Google Scholar
[26. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376:1540-1550.10.1056/NEJMoa1613878554829628423296]Search in Google Scholar
[27. Scheinberg P. Activity of eltrombopag in severe aplastic anemia. Hematology Am Soc Hematol Educ Program. 2018;1:450-456.10.1182/asheducation-2018.1.450624597530504345]Search in Google Scholar
[28. Rodgers GM, Gilreath JA. Eltrombopag as initial monotherapy for severe aplastic anemia – a case report. Ann Hematol. 2018;97:1517-1518.10.1007/s00277-018-3303-z29560523]Search in Google Scholar
[29. National Library of Medicine (U.S.) (2014 March – 2020 December). hATG+CsA vs hATG+CsA+Eltrombopag for SAA (RACE). Identifier NCT02099747. https://www.clinicaltrials.gov/ct2/show/results/NCT02099747.]Search in Google Scholar